Recently, the successful cloning of a receptor for platelet-activating factor (PAF), a lipid mediator of inflammation, was reported. Here we investigated the distribution and potential diversity of human PAF receptors (hPAF-Rs) among individual leukocyte populations by (i) hPAF-R mRNA transcription studies and (i") analysis of cell surface expression of hPAF-R protein using a polyclonal anti-peptide antibody
Platelet-activating factor (PAF) is a potent phospholipid autacoid with diverse and important physiological and pathological effects (1) . It is produced by several cell types, including monocytes, neutrophils, basophils, eosinophils, mast cells, lymphocytes, platelets, and endothelium (2) . Many of these cells that produce PAF as well as other cell types can become targets of PAF bioactions (for review, see refs. 3 and 4) . Most of the effects of PAF can be blocked by various structurally unrelated PAF-receptor (PAF-R) antagonists, indicating that PAF acts through specific receptors.
In 1991, Honda et al. (5) successfully cloned and expressed a guinea pig lung PAF-R; they showed it to be a new member of the G-protein-coupled receptor family with seven putative transmembrane domains. Subsequently, the same group (6), as well as others (7, 8) , have cloned the cDNA for a human PAF-R (hPAF-R) from human leukocyte or myeloid cell line cDNA libraries. The hPAF-R is a 342-amino acid protein (estimated Mr 39, 203) having a potential extracellular N-glycosylation site at residues 169-171.
From binding studies in various cell types, apparent Kd values of PAF-R were usually found between 0.1 nM and 10 nM. However, rank order of potency for several antagonists, sensitivity to various cations, as well as signal transduction mechanisms were found to differ among cell populations, suggesting the existence of more than one hPAF-R subtype (9, 10) . Whether an eventual diversity of PAF-R was nevertheless associated with common features of one PAF-R subtype shared among various cell populations remained unknown. To address this question, we isolated a hPAF-R cDNA and compared different, representative leukocytic cell lines for the mRNA expression pattern of this particular hPAF-R species. In addition, we developed polyclonal antibodies (Ab) to hPAF-R in order to investigate the cell surface expression of the cloned hPAF-R. In this report, we present evidence that human monocytes, neutrophils, platelets, and B cells express a shared hPAF-R mRNA species and cell surface hPAF-R protein. We also describe the successful production of specific antibody to a lipid ligand receptornamely, the human PAF-R.
MATERIALS AND METHODS Reagents. PAF (1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine) was from Bachem and N-formyl-Lmethionyl-L-leucyl-L-phenylalanine (fMLP) was from Sigma. Boston) were cultured as recommended by the suppliers.
Isolation ofPeripheral Blood Leukocytes. Human peripheral blood leukocytes from healthy volunteers were isolated by dextran sedimentation and subsequent Ficoll/Hypaque centrifugation according to Boyum (11) . Monocytes were isolated as described (12) .
hPAF-R cDNA Isolation and Northern Blot Analysis. The 895-bp Sma I fragment of the guinea pig PAF-R cDNA (ref.
5; gift ofT. Shimizu, University ofTokyo) was used to screen a AgtlO cDNA library prepared from human peripheral blood mononuclear leukocytes (gift from S. Anderson, National Institutes of Health/National Cancer Institute, Frederick, MD) under low stringency conditions. A 700-bp cDNA fragment that contained the translational start codon of the hPAF-R was isolated. Its sequence was identical to that of several hPAF-R cDNAs isolated recently (6) (7) (8) . Northern blot hybridization was performed at 68°C under conditions described previously (13 (PBS) . Purification of the IgG fraction was achieved by affinity chromatography of the antiserum or preimmune serum of the same rabbit on HiTrap protein G columns (Pharmacia). F(ab')2 or Fab fragments were generated by proteQlytic digestion of the IgG fraction using the Immuno Pure F(ab')2/Fab preparation kit (Pierce). Contaminating IgG and entire or partially digested Fc fragments were removed from the preparations by protein A affinity purification (Pierce). Small Fc fragments were discarded by dialysis against PBS at pH 7.4 (Mr cutoff 30,000).
FACScan Analysis and Immunoblotting. Cell surface expression of hPAF-R on leukocytes and leukocytic cell lines was assessed by flow cytometry as described earlier (14) . Western blots were performed according to Coffey et al. (15) .
[Ca2+], was determined as described earlier (13) .
RESULTS AND DISCUSSION hPAF-R Transcription in Leukocytic Cell Lines. Northern blots with RNA isolated from the monocytic cell line U937, the promyelocytic cell line HL-60, differentiated into granulocytes, as well as four lymphocytic cell lines-namely, Raji (B cells) , Jurkat E 6.1 and Jurkat E 77-6.8 (T cells), and YT [natural killer (NK) cells]-were hybridized with the entire hPAF-R cDNA ( Fig. 1) . Monocytic, neutrophilic, and B-lymphocytic cell lines all expressed a similar hPAF-R mRNA species of -4 kb. The T-cell and NK cell lines, which we analyzed, did not transcribe detectable levels of this mRNA.
hPAF-R Expression at the Cell Surface of Leukocytic Cell Lines and Freshly Isolated Human Leukocytes. To characterize the expression of PAF-R at the protein level, we developed polyclonal Ab against a decapeptide, hPAF-R164-173, corresponding to a segment in the second extracellular loop of the putative ternary structure of the hPAF-R. Antigen specificity of the Ab was tested by competitive ELISA. Preincubation of the antiserum in the range of the halfmaximal concentration (EC50 = 1:25,000) with increasing amounts of the free peptide progressively diminished the amount of bound Ab. Competition with 1 mM of the peptide displaced the antigen-antibody binding by 70%. Preincubation of the antiserum with unrelated peptides as well as with the carrier protein KLH had no effect (data not shown).
The anti-hPAF-R164-173 Ab recognized the native receptor at the surface of whole cells, as demonstrated by flow cytometry of U937 cells (Fig. 2) . The significant labeling of U937 cells (I) was not blocked by the PAF-R antagonist WEB 2170 (II); it was, however, competitively inhibited by 1 mM free hPAF-R164-173 peptide (III) but was not affected by unrelated peptides (IV) . The anti-hPAF-R164-173 Ab, recognizing the native hPAF-R on the cell surface with high specificity, provided the necessary tool for analyzing the hPAF-R expression on various cell types.
The cell lines, tested previously for hPAF-R gene transcription, were subjected to FACScan analysis (Fig. 3) . The monocytic cell lines U937 and THP-1, as well as the neutrophilic cell line HL-60, were all anti-hPAF-R Ab-positive. Although undifferentiated HL-60 cells transcribed only very low levels of PAF-R mRNA (compare Fig. 1 ), they expressed some PAF-R at their cell surface. The B-cell line Raji was also anti-hPAF-R Ab-positive, whereas no significant labeling was observed in the NK cell line YT or in the T-cell line Molt 4. The T-cell line Jurkat was labeled at a very low level. These latter findings are consistent with recent observations that indicate that T lymphocytes do not express PAF-R unless they are properly activated (16 To correlate the hPAF-R expression on the cell surface of peripheral blood leukocytes with the results obtained for the corresponding cell lines, we isolated leukocytic subpopulations and analyzed them by two-color immunofluorescence (Fig. 4) . Monocytes and neutrophils were labeled with the monocyte/neutrophil-specific anti-CD14 Ab as well as with the anti-hPAF-R antiserum. When compared with the control (FITC alone), almost all CD14+ monocytes and CD14+ neutrophils showed the presence of hPAF-R on the plasma membrane. In addition, purified platelets analyzed by singlecolor fluorescence were also anti-hPAF-R Ab-positive. We further analyzed a mixed population of monocyte-depleted lymphocytes, made up of T, B, and NK cells. Most CD3+ cells, representing T cells, were negative for the anti-hPAF-R Ab. In contrast, most of the B cells, stained with anti-CD20 Ab, were hPAF-R Ab-positive. Similar results were obtained using purified hPAF-R IgG (data not shown). (B) . The blots were revealed with 1251-labeled protein A and exposed for 40 h.
cell line (Fig. 5) . A single protein band of -69 kDa was labeled by the antiserum but not the preimmune serum in lysates from U937 and Raji cells. The discrepancy between the calculated mass of the hPAF-R of -39 kDa (6) and the protein detected here may be due to the predicted glycosylation in the second extracellular loop (8) . Moreover, the size of the labeled protein corresponded roughly to that of a 65-kDa PAF-binding protein isolated from human platelets by Shen et al. (18) . Fig. 6 ). This effect was not blocked by the presence of anti-hPAF-R Ab. However, the antiserum itself, at a dilution of 1:200, induced (Fig. 6A) .
Furthermore, undifferentiated HL-60 cells, which failed to respond to PAF itself, also failed to respond to the antiserum (Fig. 6B) . Additionally, anti-hPAF-R Ab induced a rise in
[Ca2+]i in the hPAF-R Ab-positive U937 cells (data not shown) as well as in the Raji cell line (Fig. 6C) . The Jurkat and YT cell lines responded neither to PAF nor to the antiserum (data not shown).
To discriminate between [Ca2+], fluxes induced by the hPAF-R Ab or by potentially bioactive lipids present in the rabbit antiserum, the IgG fraction obtained by affinity purification of the serum was tested for its ability to mobilize intracellular calcium. The IgG fraction alone induced a
[Ca2+], flux in U937 cells (Fig. 6D ) that was inhibited upon addition of the PAF-specific antagonist WEB 2170 (Fig. 6E) . A marginal effect was observed with the purified IgG fraction of the preimmune serum (Fig. 6F) . Since WEB 2170 blocked the Ca2+ effect of the hPAF-R Ab without, however, affecting Ab binding to the cell (see Fig. 2 II) , the rise in [Ca2+] seemed to be mainly mediated and induced by the PAF-R.
The ability of receptor-specific Ab to mimic the effects of the natural ligand and induce [Ca2+], fluxes is not a rare finding. It was shown, for example, for the CD3/T-cell receptor complex that Ab binding induces a perturbation of the membrane receptors that triggers an increase in inositol trisphosphates and induces the release of Ca2+ from intracellular stores (19) . Although the anti-hPAFR164 173 Ab could bind to the target receptor in the presence of WEB 2170 (see We further investigated whether desensitization of the receptor by PAF resulted in the loss of responsiveness to the anti-hPAF-R Ab. This as well as the inverse situationnamely, the loss of responsiveness to PAF after desensiti- Fig. 7A . Finally, to further analyze the underlying mechanism ofthe Ab-induced [Ca2+]i fluxes, we generated F(ab')2 and Fab fragments of anti-hPAF-R IgG. The integrity as well as the purity of the Fab and F(ab')2 fractions were monitored by SDS/PAGE (Fig. 7B) . When Fab fragments were used to stimulate U937 cells, these univalent immunoglobulins were, on a molar basis, as effective in calcium mobilization as the corresponding amount ofentire IgG (Fig. 7C ). This effect was not amplified by subsequent bridging of these fragments with either goat anti-rabbit F(ab')2 fragments or whole goat antirabbit IgG (data not shown In conclusion, the potential interest of the present work is 3-fold: (i) it describes the successful production of Ab to a G-protein-coupled receptor, a hitherto difficult task; (ii) it characterizes the phenotypic and functional hPAF-R expression on leukocyte populations and correlates it with hPAF-R gene transcription; (iii) it provides direct evidence of signal transduction mediated through the hPAF-R protein. These studies thus provide new venues for studying the expression and function of hPAF-R.
